Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development
Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.
Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.
Patients in Pennsylvania are notified that some imaging procedures may need to be delayed or rescheduled due to global shortages in medical radioisotopes.
Nov. 10, 2022 – The unexpected shut down of a nuclear reactor in Belgium is creating issues for patients in Canada...
Department of Energy Secretary Jennifer Granholm breaks ground on facility to provide radioisotopes vital to national security, research and health care.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates